Three years after enrolling its first patients, a consortium of researchers examining the growing issue of immune-related adverse events due to immune checkpoint inhibitor cancer therapy released a ...

The GINECO window-of-opportunity COLIBRI (NCT04256213) study provides compelling evidence that a neoadjuvant "priming" dose ...

Cancer immunotherapy has transformed modern oncology by harnessing body's own immune system to combat malignant disease.

Please provide your email address to receive an email when new articles are posted on . Education about immune-related adverse events associated with checkpoint inhibitor therapy for cancer is ...

According to a Phase I study led by researchers at The University of Texas MD Anderson Cancer Center, published in Nature Medicine, the novel monoclonal antibody linavonkibart has demonstrated the ...

Immune checkpoint inhibitor (ICI) pneumonitis is a potentially life-threatening immune-related adverse event associated with ICI therapy across various malignancies. ICIs enhance antitumour immunity ...

Cancer immunotherapy has historically focused on harnessing the ability of T cells to recognize and attack cancer cells. Adaptive immune checkpoint inhibitors (ICIs) unleash tumor-infiltrating ...

Scientists at the Icahn School of Medicine at Mount Sinai have identified an important immune response that helps explain why ...

UF Health Cancer Institute researchers have discovered a small compound produced naturally by gut bacteria that doubled the response to lung cancer immunotherapy treatment in mice and can now be made ...

ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug ...